Avian Influenza Vaccine Market Outlook 2030:
Avian influenza is a disease caused by bird flu type A virus, which is found in aquatic birds and subsequently causes infection in domestic poultry. The virus was first detected in China. The Asian H5N1 version was detected in the subsequent year during an outbreak in Hong Kong and since then has spread across Europe, Asia, North & South America, Africa, and the Middle East. Avian influenza can be divided into highly pathogenic and low pathogenic based on its molecular structure. Depending on the strains, the virus is divided into H5N1, H7N3, H7N7, H7N9, and H9N2. Additionally, virus of type A of subtype H5N1 is considered to be the most pathogenic avian influenza virus currently under research. Avian influenza is known to cause infection in humans through nose and mouth inhalation. The classification of avian influenza vaccines include H5 avian influenza vaccine, H7 avian influenza vaccine, and H9 avian influenza vaccine. Among manufacturing nations, China stands out as the largest supplier of avian influenza vaccines, followed by the U.S. and European Union.
Avian Influenza Vaccine Market Scope and Structure Analysis
COVID-19 Impact Analysis
Impact of COVID-19 on Animal Influenza Vaccine Market
The coronavirus pandemic is having a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally.
The COVID-19 cases are increasingly due to direct or indirect contact between humans. There has been no evidence or confirmation that animals can spread COVID-19 to humans. The myth animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been impacted largely as many manufacturers in the animal health industry are left with a significantly reduced workforce. Also, implementation of stringent government policies such as restrictions of import of raw materials from China is expected to hamper the growth of the animal health market.
Healthcare facilities are stocking up the animal-related health products, considering the high demand. This is expected to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.
Top Impacting Factors
- The growing incidence of the poultry mortality due to avian influenza coupled with a desire to consumer more poultry is paving the way for enhanced avian influenza vaccine development programs.
- Emergence of regional vaccine developers in regions such as China and India with higher consumer base provide an impetus to the market in line for an exponential growth. These developers are in line to purchase cold storage facilities and open new research centers to boost vaccine manufacturing capabilities.
- Public and private sector investments and increased strategic collaborations act as the key drivers of avian influenza vaccine market growth.
- Underdeveloped veterinary infrastructure consisting of genome facilities, vaccine design, and immunization facilities, and R&D expertise in third world economies hampers the vaccine market growth.
Key Market Trends
- The Asia-Pacific countries, including China, India, and South Korea along with Israel are witnessing the highest outbreak of avian influenza virus. This is being followed by rapid expansion in supply chain efficiencies coupled with supportive government initiatives and increase in R&D infrastructure.
- Just as the U.S. has been the leading COVID-19 vaccine developer, it finds its place as the fastest growing avian influenza market, owing to factors such as rise in awareness regarding animal welfare and animal & veterinary vaccine research-related activities across the continent.
- Rapid spread of avian influenza in an already vaccinated population such as India has resulted in both antigenic and genetic changes in the structure of the virus.
- Recent outbreak of H5N8 strain of the virus has established the fact that it came from different lineage of virus, different from the current virus spread across Europe and Asia.
Key Benefits of the Report
- This study presents the analytical depiction of the avian influenza vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Avian Influenza Vaccine Market Report
- Which are the leading players active in the avian influenza vaccine market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the avian influenza vaccine market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is avian influenza vaccine?
- What is the avian influenza vaccine market prediction in the future?
- What are the current trends and predicted trends?
Avian Influenza Vaccine Market Report Highlights
| Aspects | Details |
 By Strain |
|
 By Application |
|
 By Region |
|
 Key Market Players | Medion, Merck Animal Health, Fatro S.P.A., Cavac, Chengdu Technabank Biological Products Co. Ltd., Tianjin Ringpu Biotechnology Co. Ltd., Zoetis, PT Japfa Comfeed Indonesia Tbk, Ceva, Yebio Bioengineering Co. Ltd. |
Loading Table Of Content...
